imperatorin has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fung, KP; Li, H; Li, X; Liu, F; Sun, J; Wu, P; Zeng, X | 1 |
| Cheng, B; Gong, Y; Hu, J; Jin, L; Li, J; Lin, W; Pan, C; Pan, Z; Xu, C | 1 |
2 other study(ies) available for imperatorin and Liver Neoplasms
| Article | Year |
|---|---|
Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Furocoumarins; Hep G2 Cells; Humans; K562 Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Protein Transport; Proteolysis; Signal Transduction; Transfection; Tumor Burden; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Furocoumarins; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Plasmids; Polymerase Chain Reaction | 2016 |